Get the Stockscreener App
3.30
0.90%
-0.03
Cellectar Biosciences Inc stock is currently priced at $3.30, with a 24-hour trading volume of 636.16K.
It has seen a -0.90% decreased in the last 24 hours and a +2.80% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $3.36 pivot point. If it approaches the $3.27 support level, significant changes may occur.
Previous Close:
$3.33
Open:
$3.33
24h Volume:
636.16K
Market Cap:
$118.30M
Revenue:
-
Net Income/Loss:
$-37.75M
P/E Ratio:
-0.994
EPS:
-3.32
Net Cash Flow:
$-30.91M
1W Performance:
+7.49%
1M Performance:
+2.80%
6M Performance:
+58.65%
1Y Performance:
+127.59%
1D Range:
$3.28
$3.42
52W Range:
$1.422
$4.45
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Name
Cellectar Biosciences Inc
Sector
Industry
Phone
608 441 8120
Address
100 Campus Drive, Florham Park, NJ
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-20 | Initiated | Oppenheimer | Outperform |
| Jan-21-20 | Resumed | ROTH Capital | Buy |
| Sep-13-19 | Initiated | ROTH Capital | Buy |
| Dec-21-16 | Initiated | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Stock (CLRB) Latest News
Q2 2024 EPS Estimates for Cellectar Biosciences, Inc. Boosted by Analyst (NASDAQ:CLRB) - Defense World
Defense World
Cellectar Biosciences, Inc. to Post Q2 2024 Earnings of ($0.37) Per Share, Roth Capital Forecasts (NASDAQ:CLRB) - MarketBeat
MarketBeat
Research Analysts Set Expectations for Cellectar Biosciences, Inc.'s FY2026 Earnings (NASDAQ:CLRB) - Defense World
Defense World
Research Analysts Set Expectations for Cellectar Biosciences, Inc.'s FY2026 Earnings (NASDAQ:CLRB) - Defense World
Defense World
FY2026 Earnings Forecast for Cellectar Biosciences, Inc. Issued By Roth Capital (NASDAQ:CLRB) - MarketBeat
MarketBeat
The time has not yet come to remove your chips from the table: Cellectar Biosciences Inc (CLRB) – Sete News - SETE News
SETE News
Cellectar Biosciences Inc Stock (CLRB) Financials Data
Cellectar Biosciences Inc (CLRB) Net Income 2024
CLRB net income (TTM) was -$37.75 million for the quarter ending September 30, 2023, a -38.26% decrease year-over-year.
Cellectar Biosciences Inc (CLRB) Cash Flow 2024
CLRB recorded a free cash flow (TTM) of -$30.91 million for the quarter ending September 30, 2023, a -37.01% decrease year-over-year.
Cellectar Biosciences Inc (CLRB) Earnings per Share 2024
CLRB earnings per share (TTM) was -$3.25 for the quarter ending September 30, 2023, a +27.13% growth year-over-year.
About Cellectar Biosciences Inc
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
0.77%
1.20%
Cap:
|
Volume (24h):